Oramed Pharmaceuticals has enroled and randomised more than 50% of participants in its second Phase III ORA-D-013-2 international multicentre trial of ORMD-0801, an oral insulin capsule, to treat type 2 diabetes (T2D).
About 450 T2D patients with insufficient glycemic control, handling their condition with diet alone or with diet along with metformin monotherapy are being recruited in the ORA-D-013-2 double-blind trial.
Go deeper with GlobalData
The company’s proprietary lead candidate, ORMD-0801 is being assessed in two pivotal Phase III trials, ORA-D-013-1 and ORA-D-013-2, and can become the first treatment for diabetes by orally delivering insulin at an early stage.
The Phase III ORA-D-013-1 trial completed subject enrolment in May this year and expects to receive top line findings in January next year.
Oramed CEO Nadav Kidron said: “We are very pleased as we head into the latter half of enrolment for our ORA-D-013-2 trial, especially after having just completed 100% enrolment in our larger ORA-013-1 trial which randomised a total of 710 patients.
“Together, these trials are the world’s first Phase 3 oral insulin trials conducted under a US FDA IND.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe ORA-D-013-2 trial is being conducted under the US Food and Drug Administration (FDA) Investigational New Drug Application (IND).
In this trial, the subjects will be randomised in 1:1 two cohorts and administered with 8mg ORMD-0801 or placebo at night.
The efficacy of ORMD-0801 compared to placebo in enhancing glycemic control as evaluated by A1c over a treatment period of 26 weeks will be the trial’s primary endpoint.
Comparing the ORMD-0801 vs placebo in maintaining the glycemic control for 52-week treatment period will be the secondary endpoint of the trial.
